Mechanism of Action
LL-37 acts through membrane disruption of pathogens and receptor-mediated immunomodulation of host cells.
Antimicrobial Membrane Disruption
LL-37 has an amphipathic alpha-helical structure that inserts into bacterial membranes, disrupting membrane integrity and causing osmotic lysis. It is effective against gram-positive bacteria (Staphylococcus, Streptococcus), gram-negative bacteria (Pseudomonas, E. coli), and many fungi. Importantly, it retains activity against antibiotic-resistant strains including MRSA.[1]Toll-Like Receptor Modulation
LL-37 binds and modulates TLR2, TLR4, and TLR9, blocking excessive LPS-driven inflammation while maintaining appropriate pathogen sensing. This immunomodulatory activity reduces sepsis-associated cytokine storm while preserving antimicrobial defense, a therapeutically favorable balance.[2]Wound Healing and Angiogenesis
LL-37 promotes keratinocyte and fibroblast migration through activation of EGFR and FPRL1 receptors. It stimulates VEGF expression, promoting angiogenesis in wound beds. These pro-healing effects make it relevant for chronic non-healing wounds, diabetic ulcers, and post-surgical repair.[3]Research Overview
Wound Healing and Skin Repair
Strong EvidenceLL-37 accelerates re-epithelialization in wound models by promoting keratinocyte migration and proliferation. In diabetic wound models, LL-37 restores the impaired innate immune response at the wound site, reducing bacterial burden while promoting closure. Phase II evaluation in chronic wounds has been conducted.[3]
Antimicrobial Activity
Strong EvidenceLL-37 broad-spectrum antimicrobial activity covers 90%+ of clinical pathogen strains tested in vitro. Activity against biofilm-forming organisms (Pseudomonas in cystic fibrosis lungs, Staphylococcus in wound infections) is particularly clinically relevant as biofilms resist conventional antibiotics.[1]
Respiratory Infections and Lung Protection
Phase II ClinicalAerosolized LL-37 has been evaluated in Phase II trials for lung infections in cystic fibrosis and ventilator-associated pneumonia. Reduced bacterial counts and improved inflammatory markers observed. LL-37 deficiency in vitamin D-deficient populations is associated with increased respiratory infection susceptibility.[2]
Psoriasis and Autoimmune Relevance
Moderate EvidenceLL-37 plays a paradoxical role in psoriasis, at high skin concentrations it triggers the autoimmune cascade by forming immunogenic complexes with self-DNA. Blocking LL-37 signaling is being explored as a psoriasis treatment. Understanding this dual role is important for therapeutic application.[4]
Calculate your LL-37 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Wound healing | 100–200 µg | Once daily | SC near wound or topical |
| Immune support | 50–100 µg | Once daily | Subcutaneous |
| Respiratory / intranasal | 50–100 µg | 1–2× daily | Intranasal |
No specific meal timing required. Topical application is appropriate for skin wounds. SC administration for systemic immune support. Very short plasma half-life means local effects are primary; consider twice-daily dosing for sustained antimicrobial protocols.
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
LL-37 safety profile is favorable at research doses. It is an endogenous human peptide.
Psoriasis caution: Elevated LL-37 is a trigger in psoriasis pathogenesis. Avoid in active psoriasis or confirmed psoriatic autoimmunity.
Local irritation: Mild injection site redness and warmth are common. Usually transient.
Systemic doses: High systemic doses in animal models show cytotoxicity against mammalian cells (the mechanism is non-selective membrane disruption). Research doses are well below this threshold.
No FDA approval: Research compound. Phase II clinical investigation ongoing for specific indications.
References
- [1]Hancock RE, Sahl HG. "Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies." Nat Biotechnol. 2006;24(12):1551-1557.
- [2]Zanetti M. "Cathelicidins, multifunctional peptides of the innate immunity." J Leukoc Biol. 2004;75(1):39-48.
- [3]Steinstraesser L, et al. "Host defense peptides in wound healing." Mol Med. 2008;14(7-8):528-537.
- [4]Lande R, et al. "Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide." Nature. 2007;449(7162):564-569.